Retatrutide (10mg)

Reta peptide is a common short name for Retatrutide, also identified in research as LY3437943. It is a synthetic peptide studied for activity at GLP-1, GIP and glucagon receptors. This listing contains 10mg of lyophilised Retatrutide for in-vitro laboratory research. The vial amount is the quantity supplied, not a dose. Published batch documentation is in our CoA library.

Retatrutide is not an approved retail pharmacy medicine in Australia as checked on 15 September 2026. The TGA confirms its unapproved status. This Aussie Peptides listing is a 10mg lyophilised research vial; it is not a pre-filled pen, a Chemist Warehouse product or a prescription medicine.

As checked on 15 September 2026, the TGA states that Retatrutide has not been approved. Lilly describes it as investigational and says public release depends on clinical trials and regulatory review; no Australian release date is confirmed in that guidance. This listing supplies a lyophilised laboratory research vial, not an approved pharmacy medicine or compounded prescription product. Current research-product stock is shown on this page.

In a 2023 randomised trial of 338 adults with obesity, or overweight with a weight-related condition, Retatrutide was compared with placebo. At 48 weeks, mean body weight fell by 24.2% in the highest study group and 2.1% with placebo. Gastrointestinal adverse events were common. This was not a head-to-head trial against semaglutide or tirzepatide. Its findings concern the trial formulation and participants, not proof of safety or effectiveness for this research vial. Read the published Phase 2 study.

Retatrutide activates GLP-1, GIP and glucagon receptors. This triple-receptor profile is studied in metabolic signalling research. Receptor activity alone does not establish a clinical benefit or a safe human-use protocol. See the original receptor research.

Retatrutide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 8–12 weeks. For a general peptide reconstitution overview see our complete peptide reconstitution guide.

Store lyophilized Retatrutide vials at -20°C, away from light and moisture. After reconstitution, refrigerate at 2–8°C and use within 8–12 weeks. Do not freeze reconstituted solution.

Aussie Peptides lists Retatrutide 10mg for in-vitro laboratory research with domestic Australian dispatch. Check this page for current stock and ordering options, and the CoA library for published reports for the specific product. A research listing is not an approved medicine supply route.

Retatrutide (10mg) is priced at $144.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.

Check the current stock status and price on this page, review the vial quantity and published CoA library, then use the available ordering option. Orders from Aussie Peptides are dispatched within Australia with tracking. The product is supplied for in-vitro laboratory research only.

Yes. Body-weight change in adults with obesity was an endpoint in the published Phase 2 trial. That is clinical research on a controlled trial formulation; it does not make this laboratory vial an approved weight-loss medicine. Read the study methods and safety findings alongside its results.